Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Top Cited Papers
- 1 July 2010
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 139 (1) , 120-129.e18
- https://doi.org/10.1053/j.gastro.2010.04.013
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis CNature Genetics, 2009
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapyNature Genetics, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patientsHepatology, 2007
- Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1Gastroenterology, 2006
- Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic WhitesNew England Journal of Medicine, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialPublished by Elsevier ,2001